High Dimensional Data Section

High Dimensional Data Section

 

In 2013, the Center for Biostatistics (CFB) at The Ohio State University established the High Dimensional Data (HDD) Section to meet the pressing needs for collaborative research. The HDD Section comprises a diverse assembly of faculty and staff with a wealth of experience in collaborative research. It provides comprehensive biostatistics support for a variety of research projects encompassing basic science, translational science, and high-throughput omics studies. The primary task of the HDD Section is to collaborate with research teams in the formulation of experiment designs, hypothesis generation and testing, the development of analytical strategies, and the synthesis of research outcomes. Lianbo Yu, PhD, serves as the leader of the HDD Section, wherein he manages and provides oversight for all activities and operations within HDD.

 

Expertise

The HDD Section provides expertise in the following main areas:

 

· Statistical Methods

  • Moderated t-test for differential expression
  • Mixed model for repeated measures
  • Clustering and classification
  • Predictive modeling
  • Machine learning methods
  • Feature selection and data normalization
  • Integration of multiple data types

· Experimental Design

  • Sample size calculation
  • Power simulation
  • Multiple comparisons
  • Biomarker discovery

· Data Type Competency

  • Laboratory assay data
  • Bulk RNAseq
  • Single-Cell RNAseq
  • NanoString
  • Methylation
  • Microbiome
  • Proteomics
  • Metabolomics
  • GWAS

HDD Member

The HDD Section is comprised of a group of faculty and staff biostatisticians who provide support and develop collaborative relationships with various departments in College of Medicine and other Colleges. For a full listing of members please see “Our People” in the CFB page. For more information about HDD, email biostatistics@osumc.edu.

 

Collaboration Project Examples

· The NCI-funded program project grant (Retrovirus Models of Cancer) at OSU and Washington University aims to utilize the HTLV-1 T-cell immortalization model for diagnosis and treatment of HTLV-1 infection and ATL and related leukemia/lymphoma.

· The NCI funded program project grant (Circumventing Barriers to Effective Oncolytic Virotherapy of Malignant Gliomas) at OSU and Harvard University aims to characterize fundamental barriers and host responses that are deleterious to the efficacy of oHSV and will provide solutions that increase oHSV therapeutic effectiveness. Leveraging high-throughput profiling data encompassing RNAseq, TCRseq, BCRseq, and proteomics derived from both clinical and pre-clinical studies, the project team discern biomarkers that can accurately predict the response of GBM (glioblastoma multiforme) patients to oHSV (oncolytic herpes simplex virus) treatment.

· The NIH funded U24 grant (Interdisciplinary Research Network on Biologically Active Tau Aggregate Polymorphs from Alzheimer’s Disease and Related Dementias) at OSU and University of Texas aims to create a resource network for isolation and distribution of tau aggregate polymorphs from Alzheimer’s disease and related dementias.

· The NCI funded U54 grant (Pediatric Ohio-New York Cancer Immunotherapy Center) at OSU and Nationwide Children’s Hospital aims to develop therapeutic regimens that combine modalities to produce synergy that drives anti-tumor immune responses in preclinical pediatric cancer models, overcoming the limitations of low mutational burdens.

· The Department of Defense (DoD) funded focused program grant (Consequences of Brain Injury on Glia-neuron dynamics, Neuropathology and Neuropsychiatric Illness) at OSU aims to delineate the influence of microglia priming and reactivity to secondary immune challenges or stressors on neuronal plasticity (profile, homeostasis, and physiology) and functional recovery after TBI (mood, behavior, cognition). Utilizing scRNAseq, the project team elucidate the intricate mechanisms underlying the development of adverse consequences subsequent to TBI.

· The Food and Drug Administration (FDA) funded project (A Randomized Study of Maternal Donor Derived CMV Cytotoxic T-Lymphocytes and Valganciclovir vs Valganciclovir in Neonates With Moderate/Severe Maternal Acquired CMV Infection) at New York Medical School, OSU and Nationwide Children’s Hospital aims to determine the feasibility, safety and compare the efficacy of maternal donor-derived CMV specific CTLs plus SOC (oral valGCV) vs SOC in neonates with moderate/severe cCMV infection. The project team employ scRNAseq and CyTOF techniques to comprehensively characterize both the genomic and immunomic signatures of maternal donor derived CMV CTLs and correlate them with clinical responses, as well as long-term sequelae.